pharmaceuticals

US drug-policy shifts could cost Swiss pharma billions, study warns

An industry-backed study warns that changes to US pharmaceutical policy could cost Switzerland almost CHF95 billion by 2040. The scenarios include production moving to the United States and a new US approach to drug pricing, with potential consequences for Swiss growth and patients.

AI27 août 2026About our editorial process

AISWI swissinfo.ch

Article content structure is incomplete. Please refresh or contact support.

Sources

Study on US policies warns of billions in losses for Swiss pharma industrySWI swissinfo.ch